| A Study Evaluating the Efficacy of 5-FU + NALIRI and 5-FU + NALIRINOX for PDAC (NALPAC) (NCT05472259) | Belgian Group of Digestive Oncology | 2022-05-25 |
| Mesothelin-Specific T-Cells (FH-TCR-Tᴍsʟɴ) for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma (NCT04809766) | Fred Hutchinson Cancer Center | 2021-12-14 |
| Sonoporation and Chemotherapy for the Treatment of Pancreatic Cancer (NCT04821284) | Flemming Forsberg | 2021-12-06 |
| Study of Efficacy and Safety of NIS793 in Combination With Standard of Care (SOC) Chemotherapy in First-line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) - daNIS-2 (NCT04935359) | Novartis Pharmaceuticals | 2021-09-30 |
| A Study of ERAS-007 in Patients With Advanced Gastrointestinal Malignancies (NCT05039177) | Erasca, Inc. | 2021-09-20 |
| Safety and Efficacy of Mitazalimab in Combination With Chemotherapy in Pancreatic Cancer Patients (NCT04888312) | Alligator Bioscience AB | 2021-09-17 |
| A Study of the Safety and Tolerance of CAN04 in Combination With FOLFIRINOX in Subjects With Metastatic Pancreatic Ductal Adenocarcinoma (NCT04990037) | Cantargia AB | 2021-07-19 |
| SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem Cells (NCT04150042) | General Oncology, Inc. | 2021-01-13 |
| Niraparib and Dostarlimab for the Treatment of Germline or Somatic BRCA1/2 and PALB2 Mutated Metastatic Pancreatic Cancer (NCT04493060) | Mayo Clinic | 2020-12-28 |
| A Study of Pembrolizumab and Olaparib for People With Metastatic Pancreatic Ductal Adenocarcinoma and Homologous Recombination Deficiency or Exceptional Treatment Response to Platinum-Based Therapy (NCT04666740) | Memorial Sloan Kettering Cancer Center | 2020-12-18 |
| Eryaspase With Modified FOLFIRINOX in Advanced Pancreatic Ductal Adenocarcinoma (NCT04292743) | Georgetown University | 2020-12-02 |
| Study Evaluating the Ketogenic Diet in Patients With Metastatic Pancreatic Cancer (NCT04631445) | Translational Drug Development | 2020-12-02 |
| A Phase 1B Study of Canakinumab, Spartalizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer (PC) Patients (NCT04581343) | Pancreatic Cancer Action Network | 2020-11-02 |
| Study of Efficacy and Safety of NIS793 (With and Without Spartalizumab) in Combination With SOC Chemotherapy in First-line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) (NCT04390763) | Novartis Pharmaceuticals | 2020-10-16 |
| Study of Relacorilant in Combination With Nab-Paclitaxel in Patients With Metastatic Pancreatic Ductal Adenocarcinoma (NCT04329949) | Corcept Therapeutics | 2020-06-30 |
| Targeted Pathway Inhibition in Patients With Pancreatic Cancer (NCT04005690) | OHSU Knight Cancer Institute | 2019-08-01 |
| A Pilot Study of Ciprofloxacin Plus Gemcitabine and Nab-Paclitaxel Chemotherapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma. (NCT04523987) | National University Hospital, Singapore | 2019-02-22 |
| A Study of SLC-0111 and Gemcitabine for Metastatic Pancreatic Ductal Cancer in Subjects Positive for CAIX (NCT03450018) | British Columbia Cancer Agency | 2019-01-10 |
| Autologous Tumor Infiltrating Lymphocytes MDA-TIL in Treating Patients With Recurrent or Refractory Ovarian Cancer, Colorectal Cancer, or Pancreatic Ductal Adenocarcinoma (NCT03610490) | M.D. Anderson Cancer Center | 2018-10-16 |
| Personalized Peptide Vaccine in Treating Patients With Advanced Pancreatic Cancer or Colorectal Cancer (NCT02600949) | M.D. Anderson Cancer Center | 2016-05-11 |
| Ph1b/2 Study of PF-04136309 in Combination With Gem/Nab-P in First-line Metastatic Pancreatic Patients (NCT02732938) | Pfizer | 2016-05-04 |
| Phase Ib/II Study of MEDI4736 Evaluated in Different Combinations in Metastatic Pancreatic Ductal Carcinoma (NCT02583477) | AstraZeneca | 2016-03-25 |
| Dose-Escalation Study Of Palbociclib + Nab-Paclitaxel In mPDAC (NCT02501902) | Pfizer | 2015-11-23 |
| Phase II Study of MEDI4736 Monotherapy or in Combinations With Tremelimumab in Metastatic Pancreatic Ductal Carcinoma (NCT02558894) | AstraZeneca | 2015-11-16 |
| Gemcitabine and Nab-paclitaxel Combined With Momelotinib in Participants With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma (NCT02101021) | Sierra Oncology LLC - a GSK company | 2014-06-02 |